A hospital budget impact model to compare stem cell mobilisation strategies: impact of primary research and direct stakeholder engagementI. Jensen, Peter A. McSweeney, Ronald J. Halbert et al.|European Journal of Hospital Pharmacy|2014Cited by 2
Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program.Julien Taı̈eb, Alberto F. Sobrero, Anne Thomas et al.|Journal of Clinical Oncology|2014Cited by 1
Incorporating Stakeholder Input into Budget Impact Models to Compare Stem Cell Mobilization StrategiesInger Jensen, Peter A. McSweeney, Zhang Xiao et al.|Value in Health|2013Cited by 0